IPO-bound PharmEasy buys Thyrocare; is it worth the price and what does this means for diagnostic sector?

Several analysts and competitors Moneycontrol spoke to said that the deal would be a win-win for PharmEasy and shareholders of Thyrocare and more importantly for Velumani, the Chairman of Thyrocare, who will be cashing out.

from Moneycontrol Business News https://www.moneycontrol.com/news/business/ipo-bound pharmeasy-buys-thyrocare-is-it-worthpricewhat-does-this-means-for-diagnostic-sector_15232781.html